STOCKHOLDERS EQUITY (Tables)

6 Months Ended

Jun. 30, 2022

STOCKHOLDERS' EQUITY [Abstract]

Schedule of Assumptions

The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2022 and 2021:

	Six Months Ended June 30,
	2022			2021
Expected term	5.5 - 6.3 years			5.5 - 6.3 years
Volatility		68	%		69	%
Dividend yield		0.0			0.0
Risk-free interest rate		1.72-1.73	%		0.80-1.14	%

Schedule of Option Activity

A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2021		7,862,722		$	3.93
Forfeited		(19,371	)	$	2.24
Expired		(533,204	)	$	6.78
Granted		1,194,032		$	1.67
Options outstanding, vested and expected to vest at June 30, 2022		8,504,179		$	3.43
Options exercisable		5,825,013		$	4.04

Schedule of Unvested RSU Activity

A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2021		4,485,133		$	1.34
Granted		1,109,266		$	1.68
Vested		(812,016	)	$	1.41
Forfeited		(40,000	)	$	1.22
Balance at June 30, 2022		4,742,383		$	1.41

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and six months ended June 30, 2022 and 2021 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Research and development	$	4,898	$	42,479	$	9,569	$	147,706
Plasma center operating expenses		19,615		13,637		40,667		24,455
Selling, general and administrative		1,068,215		665,836		2,585,817		1,254,327
Cost of product revenue		98,319		83,237		196,382		160,098
Total stock-based compensation expense	$	1,191,047	$	805,189	$	2,832,435	$	1,586,586